ArticleScientific reports2025
Survival benefit of postoperative chemotherapy in stage III lung squamous cell carcinoma based on SEER database analysis through propensity score matching.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gender disparities in the overall survival of patients with minimally invasive squamous cell carcinoma of the lung: a retrospective analysis of the Surveillance, Epidemiology, and End Results Program database.Translational lung cancer research · 2026Article
- The role of the tumor microenvironment in drug resistance acquisition in lung squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung squamous cell carcinoma (LUSC) is a prevalent subtype of lung cancer. This retrospective cohort study aims to explore the effect of postoperative chemotherapy on survival in patients with Stage III LUSC and to assess its heterogeneity across different patient subgroups. Patients diagnosed with postoperative Stage III LUSC between 2010 and 2015 were identified in the Surveillance, Epidemiology, and End Results (SEER) database, and cases with missing information were excluded. The primary outcome measure was overall survival (OS). Propensity score matching (PSM) was employed to balance confounders. Kaplan-Meier (KM) curve was used to assess the OS of patients in different groups. The prognostic risk factors of patients with OS were screened and analyzed through Cox regression analysis. The cohort consisted of 1,784 patients (65.3% receiving chemotherapy), and postoperative chemotherapy was associated with a modest survival benefit: the adjusted hazard ratio (HR) was 0.62 (95%CI: 0.55-0.69, P < 0.001), corresponding to an absolute 5-year OS improvement from 28% (Non-chemotherapy) to 42% (Chemotherapy). Overall, no significant difference was observed in OS between the PSM group and the non-PSM group, except for the variable tumor size, which became significant for OS after matching. Subgroup analyses revealed that chemotherapy improved survival for patients across nearly all characteristics. Univariate and multivariate Cox regression analyses identified marital status, race, gender, and age as significant prognostic factors influencing OS. In conclusion, postoperative chemotherapy significantly ameliorates the survival in most patients with Stage III LUSC, with the most pronounced effects observed in those with N1-2 stage disease and undergoing resection of the lobe, bilobectomy, or pneumonectomy. Our findings provide valuable insights for clinical decision-making and related studies on the application of chemotherapy in patients with Stage III LUSC resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.